SEP 22, 2025 7:22 AM PDT

Exploration of tumor-immune landscape in colorectal adenocarcinoma using AI-powered multiplexed image analysis

SPONSORED BY: Leica Microsystems

Colorectal cancer is a high disease burden cancer and is the second leading cause of cancer deaths worldwide. The first-line treatment option is surgical resection of cancerous tissue. However, the clinical picture becomes more complex for recurrent disease, which occurs in roughly 20% of patients, and a variety of therapies such as adjuvants and immunotherapies have been employed to manage this manifestation of colon cancer. As a result, novel therapeutics are in demand, and a deeper understanding of the tumor microenvironment of colon cancer tissues, such as colon adenocarcinoma, or CAC, is needed.

You don't want to miss this!
To permanently access this article for free, fill out the short form below.
Access Article
ALREADY ACCESSED THIS article SIGN IN
About the Sponsor
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company's history was marked by unparalleled innovation on its way to becoming a global enterprise. Its historically close cooperation with the scientific community is the key to Leica Microsystems' tradition...
READ MORE
You May Also Like
Loading Comments...